Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (14061)	2/2/1998 9:38:00 AM
From: Henry Niman	Respond to of 32384

Wallace, LGND is very cheap right now. It's chart is already starting to change (bid is up to 11 3/8, ask is 11 1/2). CNBC is starting to mention Biotechs. LGND will see a major benefit. The big boys know where the action is.

To: Wallace Rivers who wrote (14061)	2/2/1998 9:41:00 AM
From: tonyt	Respond to of 32384

> ..looking at the chart of LGND, your analysis seems accurate. Yes. Friday LGND closed down over 40% from its recent high. Very depressing. FYI: DOW up 130, NASDAQ up 25, LGND up 1/8

To: Wallace Rivers who wrote (14061)	2/2/1998 9:56:00 AM
From: Henry Niman	Respond to of 32384

Wallace, The street is usually fairly slow at figuring out relationships. The LLY deal was in part due to pipeline pressure (Prozac goes off patent in 2002) and these deals will have long term consequences (the LLY deal was about $200 million, not counting royalties). Biotechs in general have been weak and some biotechs will be adversely affected. However, LGND's two core technologies are at the heart of big pharmas (IR technology) and Biotech's (STAT) technologies and the merger between GLX and SBH has a program in each area. However, LGND has one of the best if not the best pipelines in the industry, and this will attract the interst of companies who need products in 3-4 years (which is just about everyone). Mergers will accelerate R&D spending, as the races heat up and cutting edge Biotechs like LGND will benefit. LGND has been up 1/2 this morning already, but it's best to look at the stock long term.

To: Wallace Rivers who wrote (14061)	2/2/1998 10:47:00 AM
From: Henry Niman	Respond to of 32384

Volume is starting to pick up (130,000) and ask is back to 11 1/2.